A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis

  • STATUS
    Recruiting
  • End date
    Aug 13, 2023
  • participants needed
    159
  • sponsor
    UCB Biopharma SRL
Updated on 13 March 2022
body mass index
eczema
Accepts healthy volunteers

Summary

The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB9741 administered by intravenous infusion or subcutaneous injection to healthy study participants and following repeat dosing at a single dose level in study participants with atopic dermatitis. Furthermore, the clinical outcome in study participants with atopic dermatitis after administration of UCB9741 by intravenous infusion will be investigated.

Details
Condition Atopic Dermatitis
Treatment Subcutaneous placebo, intravenous placebo, UCB9741
Clinical Study IdentifierNCT04643457
SponsorUCB Biopharma SRL
Last Modified on13 March 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Part A
Participant must be 18 to 55 years of age inclusive at the time of signing the informed consent form (ICF)
Participant must be overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring
Participant has a body mass index (BMI) within the range 18 to 30 kg/m^2 (inclusive)
Participant can be male or female
A male participant must agree to use contraception during the Treatment Period and for at least 90 days after the final dose of investigational medicinal product (IMP), and refrain from donating sperm during this period
A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: i) Not a woman of childbearing potential (WOCBP) OR ii) A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 90 days after the final dose of IMP
Part B
Participant must be 18 to 65 years of age inclusive at the time of signing the ICF
Participant has been diagnosed with atopic dermatitis (AtD) according to American Academy of Dermatology criteria (2014), whose diagnosis was made at least 12 months prior to initiating the study (signing of the ICF), with an Eczema Area and Severity Index (EASI score) of ≥14 at Screening and ≥16 at Baseline
Participant has a body mass index (BMI) within the range 18 to 30 kg/m^2 (inclusive)
Participant can be male or female
A male participant must agree to use contraception during the Treatment Period and for at least 90 days after the final dose of IMP, and refrain from donating sperm during this period
A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: i) Not a woman of childbearing potential (WOCBP) OR ii) A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 90 days after the final dose of IMP

Exclusion Criteria

Part A
Participant has a known hypersensitivity to any components of the investigational medicinal product (IMP) or other biologic drugs as stated in this protocol
Participant has a significant allergy to humanized monoclonal antibodies (mAbs)
Participant has clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe posttreatment hypersensitivity reactions
Participant has abnormal blood pressure (BP; outside the normal range) in a supine position after 5 minutes rest
Participant has a recent history or currently active clinically-significant bacterial, fungal, endoparasite, or viral (including hospitalization for coronavirus disease 2019 (COVID-19)) infection (within 6 months of the Screening Visit)
Participant has a history of inflammatory bowel disease (includes Crohn's disease and ulcerative colitis)
Participant has a history of diabetes
Participant has a corrected QT interval (QTc) >450 msec
Participant has received any prescription or nonprescription medicines, including over the counter remedies and herbal and dietary supplements (other than vitamins within recommended daily dose limits), within 14 days (or 5 half-lives of the respective drug, whichever is longer) prior to the Baseline Visit, other than contraceptives (oral, implants, or intrauterine devices) or occasional use of analgesics, such as paracetamol (acetaminophen, with or without caffeine, with a maximal dose of 4 g/day and 10 g/14 days)
Participant has received Bacillus Calmette-Guerin vaccinations within 1 year prior to the Baseline Visit or within 90 days after the final dose of IMP
Participant has been treated with biologic agents (such as mAbs, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to the Baseline Visit
Participant has participated in another study of an IMP within the previous 90 days or 5 half-lives of the IMP (whichever longer), or is currently participating in another study of an IMP
Participant has sensitivity to heparin or heparin-induced thrombocytopenia
Part B
Participant has a known hypersensitivity to any components of the IMP or other biologic drugs as stated in this protocol
Participant has significant allergies to humanized mAbs
Participant has clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe posttreatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear Immunoglobulin A (IgA) dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis)
Participant has abnormal BP (outside the normal range) in a supine position after 5 minutes rest (systolic BP: 90 mmHg to 140 mmHg; diastolic BP: 50 mmHg to 90 mmHg; pulse rate: 40 bpm to 100 bpm). Any values marginally (eg, ≤5 mmHg) outside the normal range but considered not clinically significant by the investigator will be allowed. For values outside the permitted ranges, retesting is allowed at the discretion of the investigator. If the repeat readings are outside the normal range, the study participant will not be included in the study
Participant has a recent history of or clinically active clinically-significant bacterial, fungal, endoparasite, or viral (or any history of hospitalization for COVID-19) infection (within 6 months of the Screening Visit)
Participant has a history of inflammatory bowel disease (includes Crohn's disease and ulcerative colitis)
Participant has a history of diabetes that is not well controlled with diet or stable doses of oral medications
Participant has a corrected QT interval (QTc) >450 msec
Participant has received any prescription or nonprescription medicines, including over the counter remedies and herbal and dietary supplements (other than vitamins within recommended daily dose limits) within 14 days (or 5 half-lives of the respective drug, whichever is longer) prior to the Baseline Visit, other than contraceptives (oral, implants, or intrauterine devices) or occasional use of analgesics such as paracetamol (acetaminophen, with or without caffeine, with a maximal dose of 4 g/day and 10 g/14 days) or inhaled corticosteroids for seasonal rhinitis or inhaled bronchodilators for mild asthma
Participant has received Bacillus Calmette-Guerin vaccinations within 1 year prior to the Baseline Visit or within 90 days after the final dose of IMP
Participant has been treated with biologic agents (such as mAbs, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to the Baseline Visit
Participant has participated in another study of an IMP within the previous 90 days or 5 half-lives of IMP (whichever longer) or is currently participating in another study of an IMP
Participant has sensitivity to heparin or heparin-induced thrombocytopenia
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note